Scientists at WashU have found a new way to protect the brain from Alzheimer's damage — by blocking immune cells rather than targeting toxic tau protein. In mice, the approach preserved ~40% more brain tissue in memory regions and improved memory, even with tau tangles still present. The treatment also works from outside the brain, sidestepping the notoriously difficult blood-brain barrier problem.
Scientists at Washington University School of Medicine have identified a promising new strategy for fighting Alzheimer's: targeting the immune system's role in destroying neurons, rather than trying to clear toxic tau protein. In mice, blocking a receptor called CXCR3 — which guides harmful T cells into the brain — cut the number of infiltrating T cells by roughly half and dramatically reduced neurodegeneration, even though tau levels remained unchanged.
A companion study published in Nature Neuroscience added another piece to the puzzle, showing that these T cells are activated in lymph nodes outside the brain before traveling in. That means treatment may not need to cross the blood-brain barrier — a major hurdle in developing neurological drugs — opening the door to therapies already used in autoimmune diseases like multiple sclerosis.
By the Numbers
Why it matters: Current Alzheimer's drugs like lecanemab and donanemab target amyloid but haven't been shown to stop neurons from dying. This immune-focused approach could offer a new therapeutic lane — one that may also apply to other tauopathies where amyloid isn't even present.
